Group Raises Safety Concerns Over Hormone Treatment

Law360, New York (August 23, 2006, 12:00 AM EDT) -- A women’s health group has asked the U.S. Food and Drug Administration to put a stop to sales of estrogen and testosterone combinations made by two pharmaceutical companies used to alleviate hot flashes associated with menopause.

The National Women’s Health Network said Tuesday that it petitioned Andrew Von Eschenbach, the acting commissioner at the FDA, to halt sales of Solvay SA’s Estratest and Breckenridge Pharmaceutical’s Syntest, stating the hormone treatments lack evidence that they are safe.

“Solvay and Breckenridge continue to market Estratest and Syntest…even though...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.